Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.

<h4>Background</h4>Cabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV treatment and prevention. CAB is formulated both as an immediate-release oral tablet for daily administration and as a long-acting injectable suspension (long-acting CAB [CAB LA]) for intramu...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Raphael J Landovitz, Sue Li, Beatriz Grinsztejn, Halima Dawood, Albert Y Liu, Manya Magnus, Mina C Hosseinipour, Ravindre Panchia, Leslie Cottle, Gordon Chau, Paul Richardson, Mark A Marzinke, Craig W Hendrix, Susan H Eshleman, Yinfeng Zhang, Elizabeth Tolley, Jeremy Sugarman, Ryan Kofron, Adeola Adeyeye, David Burns, Alex R Rinehart, David Margolis, William R Spreen, Myron S Cohen, Marybeth McCauley, Joseph J Eron
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Public Library of Science (PLoS) 2018-11-01
Colecção:	PLoS Medicine
Acesso em linha:	https://doi.org/10.1371/journal.pmed.1002690
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!